Apellis Pharmaceuticals (NASDAQ:APLS) Earns “Neutral” Rating from Cantor Fitzgerald

Apellis Pharmaceuticals (NASDAQ:APLS)‘s stock had its “neutral” rating reiterated by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday,Benzinga reports.

APLS has been the subject of a number of other reports. Needham & Company LLC cut shares of Apellis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Bank of America raised shares of Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Wednesday, January 21st. Raymond James Financial lowered shares of Apellis Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a report on Wednesday, April 1st. Robert W. Baird cut Apellis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, HC Wainwright downgraded Apellis Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price target for the stock from $48.00 to $41.00 in a research note on Wednesday, April 1st. Three research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $35.72.

Apellis Pharmaceuticals Price Performance

Shares of APLS stock opened at $41.03 on Friday. The stock has a market cap of $5.25 billion, a price-to-earnings ratio of 40.23 and a beta of -0.24. The business’s fifty day moving average is $32.35 and its 200 day moving average is $26.05. Apellis Pharmaceuticals has a twelve month low of $16.10 and a twelve month high of $41.14. The company has a quick ratio of 3.16, a current ratio of 3.63 and a debt-to-equity ratio of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.29) by $0.44. The business had revenue of $268.30 million during the quarter, compared to analyst estimates of $208.91 million. Apellis Pharmaceuticals had a return on equity of 39.71% and a net margin of 12.06%. Research analysts expect that Apellis Pharmaceuticals will post -1.14 EPS for the current fiscal year.

Institutional Trading of Apellis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Kryger Capital LLC purchased a new stake in shares of Apellis Pharmaceuticals during the first quarter valued at approximately $44,253,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Apellis Pharmaceuticals in the 1st quarter worth approximately $48,360,000. Renaissance Technologies LLC lifted its position in Apellis Pharmaceuticals by 47.8% in the 1st quarter. Renaissance Technologies LLC now owns 935,958 shares of the company’s stock valued at $37,654,000 after acquiring an additional 302,900 shares in the last quarter. Gabelli Funds LLC bought a new position in Apellis Pharmaceuticals in the 1st quarter valued at approximately $12,922,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in Apellis Pharmaceuticals during the 1st quarter valued at $8,070,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.